Idex Corp /de/

IDEX maintains a conservative capital structure with a debt-to-equity ratio of 0.46 and a current ratio of 3.05, indicating strong short-term liquidity coverage. The balance sheet holds $621.3 million in cash and equivalents against $1.86 billion in long-term debt, resulting in a net debt position. Operating cash flow of $303.7 million comfortably exceeds capital expenditures of $40.7 million, generating free cash flow of $263.0 million.

Profitability metrics show a return on equity of 12.06% and a return on assets of 6.97%. The company trades at a price-to-earnings multiple of 34.17 and an EV/EBITDA of 25.38, reflecting a premium valuation relative to typical industrial peers. Gross profit stands at $824.9 million on $1.81 billion in revenue, yielding a gross margin of approximately 45.6%.

Revenue is diversified across three primary segments: Health and Science Technologies, Fluid and Metering Technologies, and Fire and Safety Diversified Products. Geographic exposure is broad, with significant operations in the United States, Europe, Asia, and other regions, mitigating single-market concentration risk. No single customer accounts for a material portion of revenue based on disclosed concentration risks.

Growth trajectory is supported by consistent revenue generation of $1.81 billion in the latest period. The company has pursued an acquisition-led growth strategy, integrating entities such as Mott Corporation, MicroLAM Inc., and Iridian Spectral Technologies to expand its technological footprint and addressable markets.

Risk factors include medium liquidity risk due to net debt levels and unknown dilution risk stemming from missing basic share count data. Key flags highlight the inability to assess dilution precisely and the negative net cash position after subtracting total debt. Forward-looking statements in filings cite risks related to macroeconomic challenges, tariffs, supply chain conditions, and integration of recent acquisitions.

Recent events include the filing of 8-K reports with material items under code 2.02, indicating changes in financial statements or management. Analyst sentiment remains positive with a mean recommendation of 2.12 (buy) and a median price target of $251.00, suggesting upside potential from the current market price of $222.22.

Analysts project 9.3% upside to a mean price target of $242.78, reflecting strong institutional confidence in the company's future performance.

A current ratio of 2.86 suggests strong short-term liquidity, providing a robust buffer against immediate financial obligations and operational shocks.

Cash conversion of 1.41 exceeds the 1.16 cohort median, highlighting the company's ability to effectively translate earnings into actual cash flow.

Net income CAGR of -8.0% from FY2023 to FY2025 signals a deteriorating profitability trend despite relatively stable revenue levels.

Long-term debt increased to $1.86 billion in FY2024, representing a significant leverage expansion compared to $1.33 billion in FY2023.

The company carries a negative book value of -$449.6 million, which may indicate significant intangible asset amortization or accumulated losses.

A medium liquidity risk flag suggests potential challenges in meeting short-term obligations under stressed market conditions.

Revenue $1.81B; Operating income $372.3M.

• ▍Revenue $1.81B
• ▍Operating income $372.3M
• ▍Net margin 14.6%

Revenue $886.9M; Operating income $172.4M.

• ▍Revenue $886.9M
• ▍Operating income $172.4M
• ▍Net margin 13.5%

Revenue $3.46B; Operating income $699.3M.

• ▍Revenue $3.46B
• ▍Operating income $699.3M
• ▍Net margin 14.0%

Revenue $3.27B; Operating income $677.2M.

• ▍Revenue $3.27B
• ▍Operating income $677.2M
• ▍Net margin 15.4%

Revenue $3.27B; Operating income $677.2M.

• ▍Revenue $3.27B
• ▍Operating income $677.2M
• ▍Net margin 15.4%

Revenue $3.27B; Operating income $732.5M.

• ▍Revenue $3.27B
• ▍Operating income $732.5M
• ▍Net margin 18.2%

Revenue $3.27B; Operating income $732.5M.

• ▍Revenue $3.27B
• ▍Operating income $732.5M
• ▍Net margin 18.2%